Trading Summary - December 19. Yet another satisfactory

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
154
Trading Summary - December 19.

Yet another satisfactory status quo day for $DIGX.

3.5M bought on the bid at .0003 from the usual insignificant paint downs and possibly one or two impatient very small holders.

A second MM put up a token marker bid to buy and absorb any paint downs from bashers and / or trades from impatient small holders.

Looks like the bashers tested the 40K and 10K from 2 x MMs by trading 1M at .0003. The MMs bought the whole amount maintaining bids of 40K and 10K.

Subsequently, a retail bidder indicated his willingness to buy 2.47M at .0003 and was successful.

Those attempting to dupe people to sell at .0002 then tested the 40K and 10K with trades of 30K and 10K at .0003 and there was no change.

204M bought at .0003 since August 23 - the majority by longs building an inventory of shares to be traded on the several runs that are likely to come in 2018.

Attention in the market today was still diverted by a stock dormant for 3 years which came off the bottom with 873M loaded at .0001 + .0002 on Friday and 762M loaded at .0002/3/4 yesterday - it traded 487M today at .0002/3/4 and has now stabilized with most flippers gone and those that want to be loaded for 2018 are. There was also jockeying for position to load up on several other stocks in my long-term repeat runner watchlist at year bottom prices. This continues to divert the scanner watchers and their buying power for now although the $DIGX .0004s make an easy target that is a good entry for those that missed the .0003s or didn't manage to create a large enough inventory of shares to trade on multiple runs throughout 2018.

All followers of $DIGX here have no excuse for not being set up for 2018 now. There has been ample opportunity to load a combination of .0003s and .0004s for 17 weeks.

As always, anything could happen at anytime. So stay sharp if you don't already have all the shares you need to make your profit expectations up to Q4 in March 2018 and thereafter in 2018. Prior warning and / or scanner alerts of any significant buys when the PR comes out will not be given on iHub but they will be alerted here immediately.

Content below the line mainly unchanged from last update - relevant to those that are new here [tense updated to reflect events now played out as predicted].

The PR associated with the 2017 Q3 - that was filed on November 16 - has not been issued yet. The PR associated with 2016 Q3 came out on December 12, 2016 - see here:

http://www.otcmarkets.com/stock/DIGX/news/DIG...08&b=y

Until the PR comes out highlighting the excellent results - and hopefully also updating future brand expansion plans - only those who were looking for the Q3 - who mostly already have their shares - have seen it.

http://www.otcmarkets.com/stock/DIGX/news/DIG...08&b=y

In due course, the Q4 results will speak for themselves and - when PR'ed to the wider investing community - we should see serious additional new interest due to the low O/S and relatively high positive revenue for a stock in this price range - just as happened for the 2016 Q4 and the 2017 Q1 and Q2. In addition, those reluctant to buy on the ask whilst they think they still have a chance of filling on the bid before the Q4 will probably change their mind in January - ask buying started on January 13 at the beginning of this year.

As previously stated, the large additional share retirement of 275M shares since Jul 31 - on top of the 150M retired Dec 2016 > May 2017 making 425M total - has not been PR'ed yet either.

Excellent update recently on the Verified Company Profile share structure at otcmarkets.com from the Transfer Agent (see new sticky #1902) - this has not been PR'ed yet to the wider investing community and has not been spotted by the inattentive on iHub:

O/S and A/S confirmed unchanged as at Nov 30, 2017.

Float same as for all the runs this year - 50M reduction since Dec 2016.

Another 275M shares retired between Jul 31 and Oct 31 (as promised).

That takes total retired to 425M since May 31 - a significant reduction on such a small A/S and O/S for a stock in this price range.

The long-term whales who trade $DIGX will continue to buy shares at any price that makes sense to them to use on multiple runs during the remainder of 2017 (there is usually a Q4 estimate + plans update in December) and throughout 2018. It is already known from posted comments and observation that at least 4 of the main whales are buying shares - on the bid and on the ask - from the impatient at year end.

As predicted, at least 4 x whales who trade $DIGX continuously throughout each year were happy to take around 100M at .0003 when a few impatient people decided to trade for a loss at .0003 on December 14.

The big boys in DIGX now probably already have an inventory of 50M>200M each for trading through to end-2017 and up to the 2017 Q4 in March 2018.

Any shares bought at .0004 will be worth an easy 150%+ profit on any of numerous runs likely to happen through to Q4. Shares bought at .0005 should easily return 100%+ at some point in 2018.

In my experience, 70M>100M (or 250M at year end for the next year) is the optimum amount to take best advantage of each run whilst keeping the 25M cheapest batches for the bigger runs next year (especially Q4 in March 2018 when the full year profits will be up). My cheapest 25M retained for next year highs will not require any shares bought above .0003 now so all others will be tradeable going forward.

As expected, the status quo has been pretty much maintained throughout the inter Q2/Q3 PR period with it making little difference to long-term traders whether shares are picked up at .0003/4/5/6 - they will see a profit on all of them by Q4 and on various runs between.

We can now look forward to additional updates on both the possible merger discussed recently and the implementation of the additional services being offered in the chiropractic chain offices - per the Strategic Growth Plan announced earlier - over the coming days, weeks and months..

$DIGX will most likely not be allowed to go to previous year-end or inter-Q lows.

In my opinion, nobody has bought $DIGX in 2017 at a price that it isn't likely to exceed in the coming months (2017 high .0013) through to the Annual Report (March 2018).

Ludicrous claims by the notorious bashers currently on iHub - "RFB", "munimi", "Crown Capital" and "surfkast" - are clearly seen as such by all serious traders and now even by most short term (next Q) iHubbers.

Debunking nonsense posted by morons on iHub, there is absolutely no need or intention to do a reverse split. The share structure is exceptionally thin - with no dilution - and the company has been buying back shares. OTC market specialists who trade $DIGX continuously would not be loading 50M>200M shares at these end-2017 prices to trade over the next 12 months if there was even the remote possibility of a reverse split.

There have never been any promotion campaigns on $DIGX in the modern era on the current business model - since the acquisition of Expressions Chiropractic & Rehab in January 2016 and I don't think there will be any. The PRs alone + OTC market off-the-bottom specialists spotting the loading on scanners, keeping accurate records and networking with other traders has proved sufficient to generate multiple runs in 2017 and should do the same in future throughout 2018.

Regardless of whether iHub posters lose interest over the coming days and weeks, detailed coverage will continue here as $DIGX remains one of my top picks for repeat profits for those that are patient and trade it to best effect (keep all cheapest batches of shares - create an inventory of shares at higher prices to trade on every run - big or small). It remains the top earner in 2017.

In addition, money is not considered "dead" by the most successful traders in the OTC market when they know it will provide a significant return further down the line because they are in a position to understand and influence - through keen observation and record keeping - what volume of shares is likely to be made available for purchase at any particular level.







American EcoFuels Inc (AEFI) Stock Research Links

AEFI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading